Sonoma Pharmaceuticals Inc (SNOA) News & EventsSNOASonoma Pharmaceuticals Inc

Sonoma Reports Q1 Revenue of $6.4M

Reports revenue $6.4M vs. $4.02M last year. "Our first quarter results demonstrate that Sonoma has reached an important inflection point," said Amy Trombly, CEO of Sonoma. "We delivered record quarterly revenue, more than doubled our U.S. business, expanded gross margins to 40%, and achieved positive adjusted EBITDA for the first time in the company's history-all while keeping operating expenses essentially flat. These results reflect the strength of our commercial strategy, the growing global adoption of hypochlorous acid products, and the operating leverage built into our business model. With new FDA clearances, expanding distribution partnerships, and a strong pipeline of commercial opportunities, we believe we are well positioned to continue delivering profitable growth."

Sonoma Pharmaceuticals Receives FDA Clearance for Microdacyn Wound Irrigation Solution

Sonoma Pharmaceuticals has received a new 510(k) clearance from the U.S. Food and Drug Administration for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations. Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare professional for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and partial thickness second degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites, and exit sites, and for moistening and lubricating absorbent wound dressings. Microdacyn Wound Irrigation Solution can also be used for OTC management of minor skin abrasions, minor lacerations, minor irritations and intact skin of the face, eyelid and eyelashes. The new 510(k) clearance expands the use case to single patient, multiple use. The 510(k) also adds new packaging configurations, including 4 oz, 8 oz, 16 oz, and 34 oz PET bottles with a polypropylene flip-top cap, and a 4 oz PET bottle with polypropylene sprayer or spray gun, each with a 24-month shelf life.

Sonoma Pharmaceuticals Prices Public Offering at Approximately $4M

Sonoma Pharmaceuticals announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4M, before deducting fees and other expenses payable by the Company. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants. Each share of common stock is being sold at a purchase price of $1.35 per share. The warrants have an exercise price of $1.35 per share. In addition, Sonoma has granted Dawson James Securities a 45-day option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any. The offering is expected to close on April 27, subject to the satisfaction of customary closing conditions. Dawson James Securities is acting as sole bookrunner for the offering.